替尔泊肽vs司美格鲁肽，谁的减重效果更加显著？

Core Viewpoint - Tirzepatide is more effective than Semaglutide for weight loss in adults with overweight or obesity, as evidenced by a study published in JAMA Internal Medicine [4][5][15] Group 1: Study Overview - The study included 18,386 participants, with 52% having type 2 diabetes and an average age of 52 years [6] - The average follow-up time was 165 days, with over 50% of participants discontinuing treatment [6] - Researchers recorded gastrointestinal adverse events, finding similar risks between both drug groups [6] Group 2: Weight Loss Results - The results showed significant advantages for the Tirzepatide group in weight loss percentages: - ≥5% weight loss: Tirzepatide ~81.8%, Semaglutide 66.5%, risk ratio 1.76 [10] - ≥10% weight loss: Tirzepatide ~62.1%, Semaglutide 37.1%, risk ratio 2.54 [10] - ≥15% weight loss: Tirzepatide ~42.3%, Semaglutide 18.1%, risk ratio 3.24 [10] - Weight changes at follow-ups were also significantly greater for Tirzepatide: - 3 months: Tirzepatide 5.9%, Semaglutide 3.6% - 6 months: Tirzepatide 10.1%, Semaglutide 5.8% - 12 months: Tirzepatide 15.3% [12] Group 3: Expert Insights - Dr. Patricia Rodriguez highlighted that patients using Tirzepatide were more than twice as likely to lose 10% of their weight compared to those using Semaglutide, and three times more likely to lose 15% [16] - Dr. Nick Stucky noted that while Tirzepatide's effectiveness is superior, both medications resulted in significant weight loss, with no difference in gastrointestinal adverse event risks [16] - Factors such as drug availability and insurance coverage may influence the choice between these medications [16]